PTAFR and non-small cell lung carcinoma: Moreover, the data demonstrating that the blockade of PAFR activation either by PAFR antagonist or PAFR specific siRNA approach only attenuated MVP release via CPAF and targeted therapy but not by PMA confirmed the absolute requirement of the PAFR in mediating targeted therapy-induced MVP release from NSCLC cell lines.